Porton Pharma Solutions Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Porton Pharma Solutions heeft een totaal eigen vermogen van CN¥5.6B en een totale schuld van CN¥1.4B, wat de schuld-eigenvermogensverhouding op 24.7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥8.9B en CN¥3.4B.

Belangrijke informatie

24.7%

Verhouding schuld/eigen vermogen

CN¥1.37b

Schuld

Rente dekkingsratio	n/a
Contant	CN¥1.40b
Aandelen	CN¥5.55b
Totaal verplichtingen	CN¥3.37b
Totaal activa	CN¥8.92b

Recente financiële gezondheidsupdates

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥3.2B ) 300363 } overtreffen de korte termijn passiva ( CN¥1.5B ).

Langlopende schulden: De kortetermijnactiva 300363 ( CN¥3.2B ) overtreffen de langetermijnschulden ( CN¥1.9B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 300363 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 300363 is de afgelopen 5 jaar gestegen van 18.5% naar 24.7%.

Schuldendekking: De operationele kasstroom van 300363 is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 300363 op haar schulden goed worden gedekt door EBIT.

Porton Pharma Solutions Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Price target increased by 34% to CN¥20.00

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Price target decreased by 29% to CN¥20.30

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Investor sentiment deteriorates as stock falls 15%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.7% to CN¥70.63

Investor sentiment improved over the past week

High number of new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 21%

Price target decreased to CN¥104

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Consensus revenue estimates increase by 52%

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

Revenue beats expectations

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13